胎球蛋白B与动脉粥样硬化研究关系的进展
Research Progress of Relationship between Fetuin B and Atherosclerosis
DOI: 10.12677/ACM.2021.1112841, PDF,   
作者: 高 韬, 柯大智*：重庆医科大学附属第二医院全科医学科，重庆；刘 瑞：重庆医科大学附属第二医院肿瘤中心，重庆
关键词: 胎球蛋白B；肝脏因子；动脉粥样硬化；Fetuin B； Hepatokine； Atherosclerosis
摘要: 动脉粥样硬化(Atherosclerosis, As)是多种心血管疾病的病理学基础，但其复杂的病理生理机制至今仍未充分明确。同时肝脏因子与心血管疾病的发生、发展存在着某种相关性，此类因子中即包括胎球蛋白B (Fetuin B)。胎球蛋白B是一种近几年发现的由肝脏分泌的糖蛋白，在炎症、组织钙化、糖脂代谢、生殖与肿瘤等方面发挥着广泛的生理病理活性。目前有研究表明胎球蛋白B可增加心血管事件的风险，但其作用机制尚不明确，因此，本文的目的是分析胎球蛋白B和As对于机体病理生理的调控效应，为此类疾病的防治提供新思路与新方案。
Abstract: Atherosclerosis (As) is the pathological basis of a variety of cardiovascular diseases (CVD). There are complex pathophysiological mechanisms of atherosclerosis, but it has not been fully defined. At the same time, there is a certain correlation between liver factors and the occurrence and development of cardiovascular diseases, including fetuin B. Fetuin B is a glycoprotein secreted by the liver, which has been found in recent years. It plays a wide range of physiological and pathological activities in inflammation, tissue calcification, glucose and lipid metabolism, reproduction and tumor. At present, studies have shown that fetuin B can increase the risk of cardiovascular events, but its mechanism is not clear. Therefore, the purpose of this study is to analyze the regulatory effect of fetuin B and as on the pathophysiology of the body, and to provide new ideas and new programs for the further prevention and treatment of such diseases.
文章引用：高韬, 刘瑞, 柯大智. 胎球蛋白B与动脉粥样硬化研究关系的进展[J]. 临床医学进展, 2021, 11(12): 5679-5684. https://doi.org/10.12677/ACM.2021.1112841

参考文献

[1] Mahmoud, M., Souilhol, C., Serbanovic-Canic, J. and Evans, P. (2019) GATA4-Twist1 Signalling in Disturbed Flow-Induced Atherosclerosis. Cardiovascular Drugs and Therapy, 33, 231-237. [Google Scholar] [CrossRef] [PubMed]
[2] Mcalpine, C.S. and Swirski, F.K. (2016) Circadian Influence on Metabolism and Inflammation in Atherosclerosis. Circulation Research, 119, 131-141. [Google Scholar] [CrossRef] 
[3] Jung, T.W., Yoo, H.J. and Choi, K.M. (2016) Implication of Hepatokines in Metabolic Disorders and Cardiovascular Diseases. BBA Clinical, 5, 108-113. [Google Scholar] [CrossRef] [PubMed]
[4] Olivier, E., Soury, E., Risler, J.L., Smih, F., Schneider, K., Lochner, K., et al. (1999) A Novel Set of Hepatic mRNAs Preferentially Expressed during an acute Inflammation in Rat Represents Mostly Intracellular Proteins. Genomics, 57, 352-364. [Google Scholar] [CrossRef] [PubMed]
[5] Dahlman, I., Eriksson, P., Kaaman, M., Jiao, H., Lindgren, C.M., Kere, J., et al. (2004) Alpha2-Heremans-Schmid Glycoprotein Gene Polymorphisms Are Associated with Adipocyte Insulin Action. Diabetologia, 47, 1974-1979. [Google Scholar] [CrossRef] [PubMed]
[6] Meex, R.C., Hoy, A.J., Morris, A., Brown, R.D., Lo, J.C.Y., Burke, M., et al. (2015) Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism. Cell Metabolism, 22, 1078-1089. [Google Scholar] [CrossRef] [PubMed]
[7] Li, Z., He, C., Liu, Y., Wang, D., Lin, M., Liu, C., et al. (2020) Association of Fetuin-B with Subclinical Atherosclerosis in Obese Chinese Adults. Journal of Atherosclerosis and Thrombosis, 27, 418-428. [Google Scholar] [CrossRef] [PubMed]
[8] Zhu, K., Wang, Y., Shu, P., Zhou, Q., Zhu, J., Zhou, W., et al. (2017) Increased Serum Levels of Fetuin B in Patients with Coronary Artery Disease. Endocrine, 58, 97-105. [Google Scholar] [CrossRef] [PubMed]
[9] Jung, S.H., Won, K.J., Lee, K.P., Kim, H.J., Seo, E.H., Lee, H.M., et al. (2015) The Serum Protein Fetuin-B Is Involved in the Development of Acute Myocardial Infarction. Clinical Science, 129, 27-38. [Google Scholar] [CrossRef] 
[10] Jung, S.H., Lee, D., Jin, H., Lee, H.M., Ko, H.M., Lee, K.-J., et al. (2020) Fetuin-B Regulates Vascular Plaque Rupture via TGF-β Receptor-Mediated Smad Pathway in Vascular Smooth Muscle cells. Pflügers Archiv—European Journal of Physiology, 472, 571-581. [Google Scholar] [CrossRef] [PubMed]
[11] Pessin, J.E. And Saltiel, A.R. (2000) Signaling Pathways in Insulin Action: Molecular Targets of Insulin Resistance. Journal of Clinical Investigation, 106, 165-169. [Google Scholar] [CrossRef] 
[12] Mathews, S.T., Chellam, N., Srinivas, P.R., Cintron, V.J., Leon, M.A., Scott Goustin, A. (2000) Alpha2-HSG, a Specific Inhibitor of Insulin Receptor Autophosphorylation, Interacts with the Insulin Receptor. Molecular and Cellular Endocrinology, 164, 87-98. [Google Scholar] [CrossRef] 
[13] Richards, J.M., Kunitake, J., Hunt, H.B., Wnorowski, A.N., Lin, D.W., Boskey, A.L., et al. (2018) Crystallinity of Hydroxyapatite Drives Myofibroblastic Activation and Calcification in Aortic Valves. Acta Biomaterialia, 71, 24-36. [Google Scholar] [CrossRef] [PubMed]
[14] Dautova, Y., Kozlova, D., Skepper, J.N., Epple, M., Bootman, M.D. and Proudfoot, D. (2014) Fetuin-A and albumin alter cytotoxic effects of calcium Phosphate Nanoparticles on Human Vascular Smooth Muscle Cells. PLoS ONE, 9, e97565. [Google Scholar] [CrossRef] [PubMed]
[15] Lee, C., Bongcam-Rudloff, E., Sollner, C., Jahnen-Dechent, W. and Claesson-Welsh, L. (2009) Type 3 Cystatins; Fetuins, Kininogen and Histidine-Rich Glycoprotein. Frontiers in Bioscience-Landmark, 14, 2911-2922. [Google Scholar] [CrossRef] [PubMed]
[16] Denecke, B., Gräber, S., Schäfer, C., Heiss, A., Wöltje, M. and Jahnen-Dechent, W. (2003) Tissue Distribution and Activity Testing Suggest a Similar but Not Identical Function of Fetuin-B and Fetuin-A. Biochemical Journal, 376, 135-145. [Google Scholar] [CrossRef] [PubMed]
[17] Luczak, M., Suszynska-Zajczyk, J., Marczak, L., Formanowicz, D., Pawliczak, E., Wanic-Kossowska, M., et al. (2016) Label-Free Quantitative Proteomics Reveals Differences in Molecular Mechanism of Atherosclerosis Related and Non-Related to Chronic Kidney Disease. International Journal of Molecular Sciences, 17, Article No. 631. [Google Scholar] [CrossRef] [PubMed]
[18] Geng, H., Zhang, X., Wang, C., Zhao, M., Yu, C., Zhang, B., et al. (2015) Even Mildly Elevated TSH Is Associated with an Atherogenic Lipid Profile in Postmenopausal Women with Subclinical Hypothyroidism. Endocrine Research, 40, 1-7. [Google Scholar] [CrossRef] [PubMed]
[19] Wang, D., Liu, Y., Liu, S., Lin, L., Liu, C., Shi, X., et al. (2018) Serum Fetuin-B Is Positively Associated with Intrahepatic Triglyceride Content and Increases the Risk of Insulin Resistance in Obese Chinese Adults: A Cross-Sectional Study. Journal of Diabetes, 10, 581-588. [Google Scholar] [CrossRef] [PubMed]
[20] Choi, J.W., Liu, H., Mukherjee, R. and Yun, J.W. (2012) Downregulation of Fetuin-B and Zinc-α2-Glycoprotein Is Linked to Impaired Fatty Acid Metabolism in Liver Cells. Cellular Physiology and Biochemistry, 30, 295-306. [Google Scholar] [CrossRef] [PubMed]
[21] Aguilar-Olivos, N.E., Carrillo-Córdova, D., Oria-Hernández, J., et al. (2015) The Nuclear Receptor FXR, But not LXR, up-Regulates Bile Acid Transporter Expression in Non-Alcoholic Fatty Liver Disease. Annals of Hepatology, 14, 487-493. [Google Scholar] [CrossRef] 
[22] Bjursell, M., Wedin, M., Admyre, T., Hermansson, M., Böttcher, G., Göransson, M., et al. (2013) Ageing FXR Deficient Mice Develop Increased Energy Expenditure, Improved Glucose Control and Liver Damage Resembling NASH. PLoS ONE, 8, Article ID: e64721. [Google Scholar] [CrossRef] [PubMed]
[23] Murakami, T., Walczak, R., Caron, S., Duhem, C., Vidal, V., Darteil, R., et al. (2007) The Farnesoid X Receptor Induces Fetuin-B Gene Expression in Human Hepatocytes. Biochemical Journal, 407, 461-469. [Google Scholar] [CrossRef] 

为你推荐